Clairvest differentiates itself through active partnership with management teams and entrepreneur stakeholders, contributing not only capital but also strategic expertise to drive portfolio company growth. The firm co-invests alongside institutional investors in owner-led businesses and pursues both majority and minority equity positions, targeting Canadian and US mid-market opportunities with EBITDA between C$10-50 million.
Cyborg Score Rationale
Clairvest maintains a strong market position as an established private equity player with substantial AUM and successful fund closures (Clairvest Equity Partners VII at US$1.2 billion). However, earnings have declined 17% annually over the past five years with compressed profit margins (7.3% vs prior 67.5%), and the stock underperformed the Canadian market return of 28.4% over the past year, suggesting headwinds in investment returns and market valuation.
Top Insights
Manages US$1.2 billion hard cap fund (Clairvest Equity Partners VII) with significant institutional co-investor base
Diversified across 40+ industry sectors reducing concentration risk but complicating operational synergies
Recent earnings pressure (17% annual decline over 5 years) and margin compression indicate portfolio or market valuation challenges
Actively executing growth equity investments in medical practice management, environmental services, and digital commerce sectors
Named Competitors
Mega-cap Private Equity — Large-scale buyouts and growth capital
Canadian Mid-Market PE — Canadian-focused acquisitions and operations